Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to determine safety and efficacy of BNCT (Novel Accelerator-based Radiation Oncology Therapy) in treatment of advanced refractory malignant tumors in China

Next Previous
Search
Trial Profile

A study to determine safety and efficacy of BNCT (Novel Accelerator-based Radiation Oncology Therapy) in treatment of advanced refractory malignant tumors in China

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antibody-boron-conjugate-radiopharmaceuticals-TAE-Life-Sciences (Primary)
  • Indications Glioma; Head and neck cancer; Malignant melanoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use

    • Most Recent Events

    • 27 Dec 2024 Added this study as its the China first AB-BNCT human clinical study
    • 03 Mar 2023 New trial record
    • 27 Feb 2023 Results, after a 3-month follow-up, the first 4 patients showed satisfactory safety and superior tumor control performance. All of them showed tumor regression. The 12 patients will have remained follow-up observation accordingly , presented in a Neuboron Medical Group media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top